Johnson & Johnson (JNJ) Expected to Announce Quarterly Earnings on Wednesday

Johnson & Johnson (NYSE:JNJ - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data before the market opens on Wednesday, July 16th. Analysts expect Johnson & Johnson to post earnings of $2.65 per share and revenue of $22.85 billion for the quarter. Johnson & Johnson has set its FY 2025 guidance at 10.500-10.700 EPS.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The firm had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. On average, analysts expect Johnson & Johnson to post $11 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Johnson & Johnson Price Performance

JNJ opened at $155.76 on Wednesday. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The company has a 50 day moving average of $153.67 and a two-hundred day moving average of $154.25. The company has a market cap of $374.77 billion, a P/E ratio of 17.33, a P/E/G ratio of 2.35 and a beta of 0.41.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.34%. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's payout ratio is currently 57.84%.

Institutional Trading of Johnson & Johnson

A hedge fund recently raised its stake in Johnson & Johnson stock. Brighton Jones LLC increased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 13.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 51,876 shares of the company's stock after acquiring an additional 6,332 shares during the period. Brighton Jones LLC's holdings in Johnson & Johnson were worth $7,502,000 at the end of the most recent reporting period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several analyst reports. Barclays decreased their target price on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Bank of America decreased their target price on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Raymond James Financial reduced their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Finally, Guggenheim reiterated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Eleven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.